Answers are grounded in this paper and cite their sources.
Osteoporosis is a highly prevalent metabolic bone disease worldwide, and its central pathological mechanism is an imbalance in bone remodeling. Mitochondrial dysfunction and ferroptosis, two key mechanisms of cellular injury, have recently been shown to jointly drive the onset and progression of osteoporosis through complex crosstalk networks. Mitochondrial dysfunction is characterized by abnormal mitochondrial dynamics, impaired oxidative phosphorylation, and defective mitophagy, whereas ferroptosis is defined by iron overload, lipid peroxidation, and glutathione peroxidase 4 (GPX4) inactivation. These processes interact in osteoblasts, osteoclasts, and osteocytes. Reactive oxygen species (ROS) signaling, iron metabolic disorder, and the mitochondria–endoplasmic reticulum stress axis play central roles in bone remodeling imbalance by coordinately regulating cell fate and bone metabolic homeostasis. This narrative review provides a structured synthesis of recent advances in the crosstalk between mitochondrial dysfunction and ferroptosis, integrating evidence from molecular biology, cell biology, animal models, and selected clinical observations. The aim is to provide a theoretical basis and identify potential intervention targets for the development of targeted therapies for osteoporosis.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: